摘要:
The present invention relates to certain polyhydroxylated pentacyclic triterpene acids of formula (I) for use as HMG-CoA reductase inhibitors in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to a reduction of the HMG-CoA reductase activity in a mammal, preferably a human being. The present invention further relates to certain mixtures and plant extracts comprising euscaphic acid and tormentic acid, wherein the amount of euscaphic acid to tormentic acid exceeds a certain ratio. Further, the present invention also relates to a formulation, preferably pharmaceutical or nutraceutical formulation, comprising one or more of said compounds of formula (I), a composition according to the present invention or a plant extract according to the present invention. Also, the present invention relates to a process for obtaining certain polyhydroxylated pentacyclic triterpene acids of formula (I), a composition according to the present invention or a plant extract according to the present invention.
摘要:
The present invention relates to certain polyhydroxylated pentacyclic triterpene acids of formula (I) for use as HMG-CoA reductase inhibitors in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to a reduction of the HMG-CoA reductase activity in a mammal, preferably a human being. The present invention further relates to certain mixtures and plant extracts comprising euscaphic acid and tormentic acid, wherein the amount of euscaphic acid to tormentic acid exceeds a certain ratio. Further, the present invention also relates to a formulation, preferably pharmaceutical or nutraceutical formulation, comprising one or more of said compounds of formula (I), a composition according to the present invention or a plant extract according to the present invention. Also, the present invention relates to a process for obtaining certain polyhydroxylated pentacyclic triterpene acids of formula (I), a composition according to the present invention or a plant extract according to the present invention.
摘要:
The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with an estrogen receptor (ER) related disease or condition of the animal or human body, as well as methods, uses and other inventions related thereto.
摘要:
The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with a phosphodiesterase (PDE) dependent disease or condition of the central nervous system, as well as methods, uses and other inventions related thereto.
摘要:
This invention provides a salutaridinol 7-O-acetyltransferase protein, a salutaridinol 7-O-acetyltransferase gene, and a sequence which is complementary thereto. This invention further provides a method for the production of thebaine comprising the steps of (i) contacting in vitro a protein having salutaridinol 7-O-acetyltransferase activity with salutaridinol and acetyl coenzyme A at pH 8 to 9, and (ii) recovering the thebaine thus produced.
摘要:
This invention provides a protein comprising consecutive amino acids, the amino acid sequence of which is illustrated in FIG. 8 (SEQ. ID No. 14) or, a fragment thereof having at least 15 amino acids, or a variant thereof, the sequence of which has at least 70% identity with the amino acid sequence of FIG. 8 (SEQ. ID No. 14) over a length of at least 400 amino acids. This invention further provides a peptide comprising a fragment of salutaridinol 7-O-acetyltransferase protein of at least 6 consecutive amino acids which is not present in other plant acetyltransferases as illustrated in FIG. 2 (SEQ. IDs No. 8 to 12). This invention further provides a nucleic acid molecule comprising consecutive nucleotides (i) the nucleic acid sequence of which is illustrated in FIG. 9 (SEQ. ID No. 13) or FIG. 10 (SEQ. ID No. 15), or (ii) a fragment thereof having a length of at least 45 nucleotides, or (iii) a variant thereof, the sequence of which has at least 70% identity with the sequence of FIG. 9 (SEQ. ID No. 13) or FIG. 10 (SEQ. ID No. 15) over a length of at least 1200 bases, or a sequence complementary to (i), (ii) or (iii), or the RNA equivalent of any of (i), (ii), or (iii). This invention further provides a nucleic acid molecule comprising a fragment of a salutaridinol 7-O-acetyltransferase gene, at least 18 consecutive nucleotides unique to the salutaridinol 7-O-acetyltransferase gene and being chosen from the 5′ or 3′ untranslated regions of the sequence illustrated in FIG. 9 (SEQ. ID No. 13), or a sequence which is complementary thereto. This invention further provides a method for producing pentacyclic morphinan alkaloids comprising (i) introducing a nucleic acid molecule encoding salutaridinol 7-O-acetyltransferase into a plant cell capable of expressing salutaridinol and/or salutaridine and/or (R)-reticuline, (ii) propagating said plant cell to produce a multiplicity of morphinan-producing cells, and (iii) recovering said morphinan(s) from said multiplicity of cells. This invention further provides a method for the production of thebaine comprising the steps of (i) contacting in vitro a protein having salutaridinol 7-O-acetyltransferase activity with salutaridinol and acetyl co-enzyme A at pH 8 to 9, and (ii) recovering the thebaine thus produced.
摘要:
The invention relates to compositions and methods (with regard to animals and humans) for utilizing an extract and/or one or more natural spiro triterpenoids and derivatives thereof alone or as a supplement. Certain materials utilized are from the blazeispirol family, obtainable from Agaricus species. Treatments include the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor, as well as corresponding methods of treatment, the manufacture of a pharmaceutical and nutraceutical formulation for said treatment. The invention also relates to the use of the extract and compound(s) in the treatment or in the preparation of a medicament (e.g. a nutraceutical) for the prophylactic and/or therapeutic treatments, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations described herein which are useful in prophylactic and therapeutic treatments. They can also be used for non-therapeutic, e.g. cosmetic, purposes.
摘要:
The invention relates to the use, or methods (especially with regard to animals, especially human, that are in need of such treatment) comprising the use, of an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from the group consisting of Schisandra, Illicium, Kadsura, Steganotaenia and Magnolia, alone or as supplement, as active ingredient in the regulation of body weight and/or fat loss and/or for the management of obesity, either in humans or in animals, to the use of said extract and/or natural compound(s) or mixtures in the manufacture of a pharmaceutical or nutraceutical formulation for the regulation of body weight and/or fat loss and/or for the management of obesity either in humans or in animals. The above extract and/or compound(s) can further be used to reduce one or more adverse metabolic parameters in a subject. The invention relates also to said extract and/or compound(s) for use in the treatment or in the preparation of a medicament for the treatment of obesity, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in the regulation of body weight and/or fat loss and/or for the management of obesity.
摘要:
Compounds obtainable from plants, e.g. of the genus Eucalyptus, or from microorganisms are shown to be useful as CNS activity modulators useful e.g. in the treatment of depression, for lifting mood and/or for increasing behavioural initiative and the like. This use and related aspects form embodiments of the invention. Also compounds as such are presented.The compounds useful are acylphloroglucine derivatives of the formula I, wherein the substituents are as defined in the description.
摘要:
This invention provides: (A) a protein the sequence of which is in FIG. 8 (SEQ. ID n° 14), or a fragment thereof having at least 15 amino acids, or a variant thereof, having at least 70% identity with FIG. 8 (SEQ. ID n° 14) over a length of at least 400 amino acids; (B) a peptide comprising a fragment of salutaridinol 7-O-acetyltransferase of at least 6 consecutive amino acids not present in other plant acetyltransferases as in FIG. 2 (SEQ. IDs n° 8 to 12); (C) a nucleic acid (i) the sequence of which is in FIG. 9 (SEQ. ID n° 13) or FIG. 10 (SEQ. ID n° 15), or (ii) a fragment thereof of at least 45 nucleotides, or (iii) a variant thereof, having at least 70% identity with FIG. 9 (SEQ. ID n° 13) or FIG. 10 (SEQ. ID n° 15) over a length of at least 1200 bases, or (iv) a sequence complementary to (i), (ii) or (iii); or (v) the RNA equivalent of any of (i), (ii), or (iii); (D) a nucleic acid comprising a fragment of a salutaridinol 7-O-acetyltransferase gene of at least 18 consecutive nucleotides unique to the salutaridinol 7-O-acetyltransferase gene from the 5′ or 3′ untranslated regions in FIG. 9 (SEQ. ID n° 13), or a sequence complementary thereto. This invention also provides methods for producing pentacyclic morphinan alkaloids and thebaine.
摘要翻译:本发明提供:(A)其序列在图1中的蛋白质。 8(SEQ ID NO 14)或其具有至少15个氨基酸的片段,或其变体与图1至少具有70%的同一性。 8(SEQ ID NO:14),长度至少为400个氨基酸; (B)包含不存在于如图1所示的其它植物乙酰转移酶中的至少6个连续氨基酸的salutaridinol 7-O-乙酰转移酶片段的肽。 2(SEQ ID NO 8至12); (C)核酸(i)其序列在图1中。 9(SEQ ID NO:13)或图9。 10(SEQ ID NO:15),或(ii)至少45个核苷酸的片段,或(iii)其变体与图1至少具有70%的同一性。 9(SEQ ID NO:13)或图9。 10(SEQ ID NO:15),长度至少为1200个碱基,或(iv)与(i),(ii)或(iii)互补的序列; 或(v)(i),(ii)或(iii)中任何一种的RNA当量; (D)包含图5中5'或3'非翻译区的salutaridinol 7-O-乙酰转移酶基因独特的至少18个连续核苷酸的salutaridinol 7-O-乙酰转移酶基因片段的核酸。 9(SEQ ID NO:13)或其互补序列。 本发明还提供了生产五环吗啡生物碱和蒂巴因的方法。